Get the Stockscreener App
8.32
4.81%
-0.42
Cullinan Therapeutics Inc stock is traded at $8.32, with a volume of 227.09K.
It is down -4.81% in the last 24 hours and up +10.93% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$8.74
Open:
$8.62
24h Volume:
227.09K
Relative Volume:
0.53
Market Cap:
$532.90M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-2.2547
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
-7.86%
1M Performance:
+10.93%
6M Performance:
-27.59%
1Y Performance:
-56.26%
1-Day Range:
$8.29
$8.77
1-Week Range:
$8.29
$9.25
52-Week Range:
$6.85
$21.01
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
8.32 | 532.90M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World
Cullinan Management Holds Annual Stockholders Meeting - TipRanks
Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech
California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating and $22 Price Target | CGEM Stock News - GuruFocus
Stifel Recommends Buy Rating for Cullinan Therapeutics (CGEM) | CGEM Stock News - GuruFocus
Two Sigma Investments LP Has $514,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Squarepoint Ops LLC Sells 11,673 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Two Sigma Advisers LP Grows Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MENAFN.com
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix By Stocktwits - Investing.com India
Transcript : Cullinan Therapeutics, Inc.Special Call - marketscreener.com
Cullinan expands autoimmune focus with new T cell engager license By Investing.com - Investing.com South Africa
Cullinan (CGEM) Secures Global Rights for Velinotamig from Genri - GuruFocus
Cullinan Therapeutics (CGEM) Secures Exclusive License for Velin - GuruFocus
Cullinan expands autoimmune focus with new T cell engager license - Investing.com Australia
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical - GuruFocus
Cullinan Therapeutics (CGEM) Secures Exclusive License for Velinotamig Development | CGEM Stock News - GuruFocus
Cullinan Management Enters Global License Agreement with Genrix - TipRanks
Cullinan in pact for multiple myeloma drug (CGEM:NASDAQ) - Seeking Alpha
Cullinan Therapeutics Licenses Rights to Velinotamig - marketscreener.com
Cullinan Therapeutics Licenses Rights to Velinotamig, a - GlobeNewswire
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific ... - Eagle-Tribune
Bank of America Corp DE Cuts Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Nuveen Asset Management LLC - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Decline in Short Interest - Defense World
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILI - GuruFocus
Cullinan Therapeutics IncTaiho Oncology And Cullinan Therapeutics Publish Positive Rezilient1 Trial Results - marketscreener.com
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - PR Newswire
ProShare Advisors LLC Acquires 4,124 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics to Host Analyst and Investor Event at - GlobeNewswire
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 - GuruFocus
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference | CGEM Stock News - GuruFocus
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Ameriprise Financial Inc. Raises Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (CGEM) Reveals Promising Phase 2b Results - GuruFocus
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology - GuruFocus
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology Announce Positive Results from REZILIENT1 Trial of Zipalertinib in Advanced Lung Cancer Patients - Nasdaq
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 - GlobeNewswire
Northern Trust Corp Raises Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
115,000 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Acquired by BNP Paribas Financial Markets - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World
Cullinan Therapeutics (CGEM) Projected to Announce Quarterly Earnings on Wednesday - Defense World
Cullinan Therapeutics (CGEM): UBS Lowers Price Target but Mainta - GuruFocus
Cullinan Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):